Neoadjuvant Treatment Pegylated Liposomal Doxorubicin Plus Cyclophosphamide Sequential Docetaxel Plus Trastuzumab and Pertuzumab Versus Docetaxel Plus Carboplatin Combined With Trastuzumab and Pertuzumab in HER-2 Positive Breast Cancer
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: pegylated liposomal doxorubicin (PLD)|DRUG: cyclophosphamide (C)|DRUG: trastuzumab (H)|DRUG: pertuzumab (P)|DRUG: docetaxel (T)|DRUG: docetaxel (T)|DRUG: carboplatin (Cb)|DRUG: trastuzumab (H)|DRUG: pertuzumab (P)
Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Collaborators: CSPC Ouyi Pharmaceutical Co., Ltd.